Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

C&EN 中文版

药明康德子公司合全药业计划在特拉华州建立药物化学生产基地

这是该中国公司继收购百时美施贵宝（BMS）瑞士工厂之后，在美国开展的主要项目

by Rick Mullin
June 28, 2021 | A version of this story appeared in Volume 99, Issue 25
Advertisement

Most Popular in Business

 

A technician wearing protective clothing operates a machine at a WuXi AppTec drug manufacturing plant in Shanghai.
Credit: WuXi AppTec
药明康德的一名技术人员在位于上海金山地区的生产基地工作。 特拉华州生产基地将成为药明康德子公司合全药业在全球布局的第八家工厂。

请访问cenm.ag/chinese或关注ACS微信订阅号获取更多《化学与化工新闻》的中文内容.

作为全球制药服务公司巨头药明康德的小分子药物子公司，合全药业计划在特拉华州米德尔顿建设生产基地。 在特拉华州批准了 1900 万美元的拨款支持该项目后，合全药业周一宣布了该项目。

该生产基地预计将于 2024 年开业，到 2026 年将雇佣约 500 名员工，是合全药业国际扩张的重要一步。 药明康德合全药业业务总部设在中国，并在那里经营多个生产基地。 2016 年，它在圣地亚哥开设了一家小型工厂。 今年早些时候，它同意购买位于瑞士的一家百时美施贵宝工厂。

除了生产原料药外（产能未知），特拉华州生产基地还将设有用于包装固体剂型和无菌药物的测试实验室和工厂。 药明康德表示，其长期计划会在该基地创造 1,000 个工作岗位，正在建设中的该基地位于威尔明顿以南 50 公里的工业区，占地约 75 公顷。

“特拉华州有训练有素的制药劳动力，并且临近我们的众多客户， 这些都为支持该地区的经济增长和推进该地区药物开发和制造提供了巨大的机会，”合全药业首席执行官陈民章在一份新闻稿中说。

通过进一步向中国以外的地区扩张，合全药业正在效仿其它药明康德业务。 药明康德于 2014 年在费城开设了一家免疫治疗疗法生产工厂，并于今年早些时候收购了英国细胞和基因治疗技术公司 Oxgene。 近年来，药明康德还收购了美国的实验室检测和临床研究业务。

咨询公司 “化学与制药解决方案”（Chemical and Pharmaceutical Solutions） 的负责人 James Bruno 表示，随着其制造业务进军欧洲和美国，合全药业一直在努力扩大其技术基础。 “我听说他们正在努力寻求在寡核苷酸和肽等领域的整体发展，而且实际上正在寻找肽化学家，”他说。 “他们想成为一名国际参赛者，并且他们正在尽其所能来实现目标。”

该报道由李杰为C&EN翻译。文章的原始英文版本如下。.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society

You might also like...

Outsourcing
Indian drug services companies pull in cash
Outsourcing
WuXi companies plan to divest businesses
Outsourcing
Lonza to exit drug capsule business

Article:

This article has been sent to the following recipient:

2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE